Vireo Growth Inc. (VREOF) Stock Analysis

Vireo Growth Inc. (VREOF) Healthcare & Pipeline Overview

Vireo Growth Inc. is a leading cannabis company focused on the cultivation and distribution of medical and adult-use cannabis products, operating in key U.S. markets like Maryland, Minnesota, and New York, with a commitment to quality and compliance.

What Is the Investment Thesis for VREOF?

With a market capitalization of $461M and a P/E ratio of 7.07, the company is positioned favorably compared to industry peers. Vireo's gross margin of 49.6% indicates efficient operations, although it currently faces challenges with a profit margin of -23.3%. The company is strategically positioned in the growing cannabis market, which is expected to expand significantly as legalization efforts continue across the U.S. Vireo's focus on quality and compliance enhances its competitive edge, while its established presence in Maryland, Minnesota, and New York provides a solid foundation for future growth. Key catalysts include potential regulatory changes that could expand market access and an increase in consumer demand for cannabis products. However, investors should remain aware of the ongoing risks associated with regulatory uncertainty and market volatility.

Based on FMP financials and quantitative analysis

VREOF Key Highlights

Market capitalization of $461M, indicating a solid market presence.

• P/E ratio of 7.07, suggesting potential undervaluation relative to peers.
• Gross margin of 49.6%, reflecting strong operational efficiency.
• Negative profit margin of -23.3%, highlighting current financial challenges.
• Beta of 0.38, indicating lower volatility compared to the broader market.

Who Are VREOF's Competitors?

VREOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VREOF's Key Strengths?

Strong operational capabilities in cultivation and manufacturing.

• Established presence in key cannabis markets.
• Commitment to quality and compliance enhances brand trust.

What Are VREOF's Weaknesses?

Current negative profit margin indicating financial challenges.

• Limited geographic presence compared to larger competitors.
• Dependence on regulatory environment for growth.

What Could Drive VREOF Stock Higher?

Potential regulatory changes that could expand market access.

• Increasing consumer demand for cannabis products as legalization spreads.
• Introduction of new product lines to diversify offerings.
• Strategic partnerships to enhance distribution channels.
• Expansion into new states as legalization efforts progress.

What Are the Key Risks for VREOF?

Financial-distress signal — its Altman Z-Score of 0.44 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-20.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Regulatory uncertainty impacting market operations.
• Intense competition from larger, established cannabis companies.
• Market volatility affecting consumer spending habits.
• Dependence on state-level regulations for growth opportunities.

What Are the Growth Opportunities for VREOF?

• Geographic Expansion: Vireo Growth Inc. is strategically positioned to expand its operations into additional states as cannabis legalization efforts continue. The U.S. cannabis market is projected to grow at a CAGR of 21% through 2025, providing significant opportunities for companies that can enter new markets. Vireo's established brand and operational expertise will facilitate this expansion, allowing the company to capture new customer segments and increase revenue streams.
• Product Diversification: Vireo has the opportunity to diversify its product offerings by introducing new cannabis-infused products, including edibles, beverages, and wellness products. By leveraging its manufacturing capabilities and expertise, Vireo can meet the evolving preferences of consumers and tap into this lucrative segment.
• Partnerships and Collaborations: Forming strategic partnerships with other cannabis companies, retailers, or health organizations can enhance Vireo's market position. Collaborations can lead to increased distribution channels and access to new customer bases. This approach can accelerate growth and improve Vireo's competitive advantage in the rapidly evolving cannabis market.
• Technological Advancements: Investing in advanced cultivation and production technologies can improve operational efficiency and product quality. By adopting innovative growing techniques and processing methods, Vireo can enhance its product offerings and reduce costs. This focus on technology can lead to higher profit margins and a stronger market position.
• Regulatory Changes: Changes in cannabis regulations at the federal and state levels can create new opportunities for Vireo Growth Inc. As more states legalize cannabis, Vireo can capitalize on increased demand for its products. Staying ahead of regulatory developments will be crucial for Vireo to maximize its growth potential in this evolving landscape.

What Are VREOF's Competitive Advantages?

• Established brand recognition in the cannabis market.
• Commitment to quality and compliance with regulatory standards.
• Experienced management team with industry expertise.
• Diverse product offerings catering to various consumer needs.

What Does VREOF Do?

Vireo Growth Inc., founded in 2004 and headquartered in Minneapolis, Minnesota, operates as a prominent player in the cannabis industry. Originally known as Goodness Growth Holdings, Inc., the company rebranded to Vireo Growth Inc. in July 2024 to better reflect its focus on growth and innovation in the cannabis sector. Vireo cultivates, manufactures, processes, and distributes a diverse range of medical and adult-use cannabis products, serving customers through a network of retail dispensaries and distributors across Maryland, Minnesota, and New York. The company's commitment to quality is evident in its rigorous cultivation and production processes, which adhere to strict regulatory standards. Vireo's product offerings include a variety of cannabis strains, oils, edibles, and other infused products designed to meet the needs of both medical patients and recreational users. With a workforce of 419 employees, Vireo is positioned to capitalize on the expanding cannabis market, which continues to see increasing demand as more states legalize cannabis for both medical and recreational use. The company aims to leverage its established operations and brand recognition to enhance its market share and drive future growth.

What Products and Services Does VREOF Offer?

• Cultivates medical and adult-use cannabis products.
• Manufactures a variety of cannabis-infused products.
• Processes cannabis for distribution to retail dispensaries.
• Operates in key markets including Maryland, Minnesota, and New York.
• Sells products through a network of retail dispensaries and distributors.
• Focuses on quality and compliance in all operations.

How Does VREOF Make Money?

• Revenue generated from the sale of cannabis products to retail dispensaries.
• Manufacturing and processing cannabis products for distribution.
• Potential partnerships with other companies to expand market reach.
• Focus on both medical and recreational cannabis markets.

What Industry Does VREOF Operate In?

The cannabis industry is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis products for both medical and recreational use. Vireo Growth Inc. operates within this dynamic environment, facing competition from other cannabis producers but differentiating itself through a commitment to quality and compliance. As consumer preferences shift towards legal cannabis products, companies like Vireo are well-positioned to capture market share and drive revenue growth.

Who Are VREOF's Key Customers?

• Medical cannabis patients seeking therapeutic products.
• Recreational cannabis users looking for quality products.
• Retail dispensaries that stock Vireo's products.
• Distributors that partner with Vireo for product distribution.

Company Profile

Vireo Growth Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO John Mazarakis. VREOF has traded publicly since 2019.

Return on equity for Vireo Growth Inc. stands at -20.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -25.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.3%, the inverse of the P/E and a quick read on earnings relative to price.

VREOF Valuation & Market Position

With a $461M market cap, Vireo Growth Inc. sits in the small-cap segment of the market.

Quarterly Financial Performance: Vireo Growth Inc.

Revenue for Vireo Growth Inc. came in at $209.3M during Q2 FY2026, a 97.1% improvement versus the preceding quarter. The company recorded a net loss of $97K, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, VREOF averaged $-0.49 in diluted EPS.

Vireo Growth Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.44 places it in the distress zone, a signal of elevated financial risk.

Vireo Growth Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 174.2% below estimates on average.

Over the past six months, Vireo Growth Inc. insiders filed 20 SEC Form 4 transactions — 4 sales and 16 purchases. On net that is roughly 1.3M shares acquired (about $237K) — insiders putting money in tends to read as conviction.

VREOF Financials

VREOF Latest News

VREOF Analyst Consensus

VREOF MoonshotScore

VREOF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources